Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance

Hidekata Yasuoka, Y. Sugano, T. Oka, C. Watanabe, Yuko Kaneko, T. Nojima, M. Matsumura, T. Fujii, T. Mimori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have previously described that novel autoantibodies to calpastatin (endogenous inhibitor for calcium-dependent neutral protease, calpain) were detected in patients with rheumatoid arthritis (RA) and other disorders. Since calpain is thought to mediate inflammatory process and cartilage destruction, autoantibodies to its inhibitor protein, calpastatin, may be involved in the pathogenic mechanism of rheumatoid arthritis. In the present study, we analyzed antigenic epitopes reactive with autoantibodies to calpastatin and their clinical correlation. cDNA encoding the C-terminal 178 amino acids of human calpastatin (RA-6) was digested by restriction enzymes and ligated into pEX expression vectors. These recombinant plasmids were tranfected into E. coli POP2136 and screened by colony blots using RA sera containing anti-calpastatin antibodies and a mouse monoclonal antibody. RA patient sera recognized the C-terminus of domain IV (epitope C1 ; aa. 647~673) and C-terminus of domain III (epitope C2; aa. 496~571), whereas the mouse monoclonal antibody recognized an entirely different region containing the calpain-binding site (epitope B2; aa. 572~625). To evaluate epitope reactivity of patient autoantibodies, 15 RA sera containing anti- calpastatin were reacted with epitope fusion proteins. In immunoblotting, most RA sera recognized either C1 or C2 epitopes (67% and 40%, respectively), and only one patient recognized both epitopes. B2 epitope was non-reactive with patient sera. RA patients whose sera rested with the C1 epitope represented a more progressed and severe state of arthritis than those not reacting with C1. These results suggests that anti-calpastatin antibodies may play a role in the pathogenic mechanisms of RA and their epitope reactivity may be important for disease progression.

Original languageEnglish
Pages (from-to)458-466
Number of pages9
JournalRyumachi
Volume37
Issue number3
Publication statusPublished - 1997

Fingerprint

Autoantibodies
Epitopes
Rheumatoid Arthritis
Calpain
Serum
Anti-Idiotypic Antibodies
calpastatin
Monoclonal Antibodies
Immunoblotting
Arthritis
Cartilage
Disease Progression
Proteins
Plasmids
Complementary DNA
Binding Sites
Escherichia coli
Amino Acids
Enzymes

Keywords

  • Antigenic epitope
  • Autoantibody
  • Calpain
  • Calpastatin
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Yasuoka, H., Sugano, Y., Oka, T., Watanabe, C., Kaneko, Y., Nojima, T., ... Mimori, T. (1997). Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance. Ryumachi, 37(3), 458-466.

Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance. / Yasuoka, Hidekata; Sugano, Y.; Oka, T.; Watanabe, C.; Kaneko, Yuko; Nojima, T.; Matsumura, M.; Fujii, T.; Mimori, T.

In: Ryumachi, Vol. 37, No. 3, 1997, p. 458-466.

Research output: Contribution to journalArticle

Yasuoka, H, Sugano, Y, Oka, T, Watanabe, C, Kaneko, Y, Nojima, T, Matsumura, M, Fujii, T & Mimori, T 1997, 'Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance', Ryumachi, vol. 37, no. 3, pp. 458-466.
Yasuoka, Hidekata ; Sugano, Y. ; Oka, T. ; Watanabe, C. ; Kaneko, Yuko ; Nojima, T. ; Matsumura, M. ; Fujii, T. ; Mimori, T. / Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance. In: Ryumachi. 1997 ; Vol. 37, No. 3. pp. 458-466.
@article{454e361e6c0e46f58d06aaec1ed3d7d2,
title = "Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance",
abstract = "We have previously described that novel autoantibodies to calpastatin (endogenous inhibitor for calcium-dependent neutral protease, calpain) were detected in patients with rheumatoid arthritis (RA) and other disorders. Since calpain is thought to mediate inflammatory process and cartilage destruction, autoantibodies to its inhibitor protein, calpastatin, may be involved in the pathogenic mechanism of rheumatoid arthritis. In the present study, we analyzed antigenic epitopes reactive with autoantibodies to calpastatin and their clinical correlation. cDNA encoding the C-terminal 178 amino acids of human calpastatin (RA-6) was digested by restriction enzymes and ligated into pEX expression vectors. These recombinant plasmids were tranfected into E. coli POP2136 and screened by colony blots using RA sera containing anti-calpastatin antibodies and a mouse monoclonal antibody. RA patient sera recognized the C-terminus of domain IV (epitope C1 ; aa. 647~673) and C-terminus of domain III (epitope C2; aa. 496~571), whereas the mouse monoclonal antibody recognized an entirely different region containing the calpain-binding site (epitope B2; aa. 572~625). To evaluate epitope reactivity of patient autoantibodies, 15 RA sera containing anti- calpastatin were reacted with epitope fusion proteins. In immunoblotting, most RA sera recognized either C1 or C2 epitopes (67{\%} and 40{\%}, respectively), and only one patient recognized both epitopes. B2 epitope was non-reactive with patient sera. RA patients whose sera rested with the C1 epitope represented a more progressed and severe state of arthritis than those not reacting with C1. These results suggests that anti-calpastatin antibodies may play a role in the pathogenic mechanisms of RA and their epitope reactivity may be important for disease progression.",
keywords = "Antigenic epitope, Autoantibody, Calpain, Calpastatin, Rheumatoid arthritis",
author = "Hidekata Yasuoka and Y. Sugano and T. Oka and C. Watanabe and Yuko Kaneko and T. Nojima and M. Matsumura and T. Fujii and T. Mimori",
year = "1997",
language = "English",
volume = "37",
pages = "458--466",
journal = "Ryumachi",
issn = "0300-9157",
publisher = "Nihon Ryumachi Gakkai",
number = "3",

}

TY - JOUR

T1 - Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance

AU - Yasuoka, Hidekata

AU - Sugano, Y.

AU - Oka, T.

AU - Watanabe, C.

AU - Kaneko, Yuko

AU - Nojima, T.

AU - Matsumura, M.

AU - Fujii, T.

AU - Mimori, T.

PY - 1997

Y1 - 1997

N2 - We have previously described that novel autoantibodies to calpastatin (endogenous inhibitor for calcium-dependent neutral protease, calpain) were detected in patients with rheumatoid arthritis (RA) and other disorders. Since calpain is thought to mediate inflammatory process and cartilage destruction, autoantibodies to its inhibitor protein, calpastatin, may be involved in the pathogenic mechanism of rheumatoid arthritis. In the present study, we analyzed antigenic epitopes reactive with autoantibodies to calpastatin and their clinical correlation. cDNA encoding the C-terminal 178 amino acids of human calpastatin (RA-6) was digested by restriction enzymes and ligated into pEX expression vectors. These recombinant plasmids were tranfected into E. coli POP2136 and screened by colony blots using RA sera containing anti-calpastatin antibodies and a mouse monoclonal antibody. RA patient sera recognized the C-terminus of domain IV (epitope C1 ; aa. 647~673) and C-terminus of domain III (epitope C2; aa. 496~571), whereas the mouse monoclonal antibody recognized an entirely different region containing the calpain-binding site (epitope B2; aa. 572~625). To evaluate epitope reactivity of patient autoantibodies, 15 RA sera containing anti- calpastatin were reacted with epitope fusion proteins. In immunoblotting, most RA sera recognized either C1 or C2 epitopes (67% and 40%, respectively), and only one patient recognized both epitopes. B2 epitope was non-reactive with patient sera. RA patients whose sera rested with the C1 epitope represented a more progressed and severe state of arthritis than those not reacting with C1. These results suggests that anti-calpastatin antibodies may play a role in the pathogenic mechanisms of RA and their epitope reactivity may be important for disease progression.

AB - We have previously described that novel autoantibodies to calpastatin (endogenous inhibitor for calcium-dependent neutral protease, calpain) were detected in patients with rheumatoid arthritis (RA) and other disorders. Since calpain is thought to mediate inflammatory process and cartilage destruction, autoantibodies to its inhibitor protein, calpastatin, may be involved in the pathogenic mechanism of rheumatoid arthritis. In the present study, we analyzed antigenic epitopes reactive with autoantibodies to calpastatin and their clinical correlation. cDNA encoding the C-terminal 178 amino acids of human calpastatin (RA-6) was digested by restriction enzymes and ligated into pEX expression vectors. These recombinant plasmids were tranfected into E. coli POP2136 and screened by colony blots using RA sera containing anti-calpastatin antibodies and a mouse monoclonal antibody. RA patient sera recognized the C-terminus of domain IV (epitope C1 ; aa. 647~673) and C-terminus of domain III (epitope C2; aa. 496~571), whereas the mouse monoclonal antibody recognized an entirely different region containing the calpain-binding site (epitope B2; aa. 572~625). To evaluate epitope reactivity of patient autoantibodies, 15 RA sera containing anti- calpastatin were reacted with epitope fusion proteins. In immunoblotting, most RA sera recognized either C1 or C2 epitopes (67% and 40%, respectively), and only one patient recognized both epitopes. B2 epitope was non-reactive with patient sera. RA patients whose sera rested with the C1 epitope represented a more progressed and severe state of arthritis than those not reacting with C1. These results suggests that anti-calpastatin antibodies may play a role in the pathogenic mechanisms of RA and their epitope reactivity may be important for disease progression.

KW - Antigenic epitope

KW - Autoantibody

KW - Calpain

KW - Calpastatin

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0030855753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030855753&partnerID=8YFLogxK

M3 - Article

C2 - 9256029

AN - SCOPUS:0030855753

VL - 37

SP - 458

EP - 466

JO - Ryumachi

JF - Ryumachi

SN - 0300-9157

IS - 3

ER -